Internship Program Connects With Industry at MCN

Internship Program Connects With Industry at MCN

November 01, 2014

Extract from the Melbourne Centre for Nanofabrication:

MCN’s internship program has hit the ground running, with four interns recently joining MCN’s professional staff. With a range of experience in nanotechnology, chemical engineering and physics, the interns were selected by our industry partners to work on projects particular to their skills. MCN welcomes James Grifftih, Mathew Lui, Lachlan Pierce and Siew Pei Hoo!

Both Lachlan and Siew will be working with Trajan Scientific and Medical which is focused on developing and commercialising technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements, especially those that can lead to portability, miniaturisation and affordability.

Trajan engaged with MCN to continue development of porous polymer monoliths designed as a means of chemical separation, and to take this work from the research domain into a viable manufactured product. General manager of chemistry platforms at Trajan, Dr. Rick Barber said, “MCN is a fundamental interface between the research world and the manufacturing line. The intern program is a fantastic opportunity for us to fast track the research and development stage of this project as we are able to work on parallel applications and work through the initial research work faster, to achieve an end-product more swiftly.”

Read the full article at the MCN website.

View more of Trajan's collaborative programs on our Partnerships page.

MCN Interns at Trajan with Research Scientist Dr Jason Hon and General Manager Chemistry Platforms Dr Rick Barber

Photo (L-R): Dr Jason Hon, Research Scientist, Trajan, Siew Pei Hoo, MCN Intern, Lachlan Pierce, MCN Intern, and Dr Rick Barber, General Manager, Chemistry Platforms, Trajan, at Trajan Scientific and Medical, Melbourne, Australia.




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More